renal pelvis carcinoma

Renal pelvis carcinoma, also known as transitional cell carcinoma of the renal pelvis and ureter, can exhibit a range of signs and symptoms. These may include:

• Blood in the urine (hematuria) [1, 7, 8]
• Back pain that persists or worsens over time [5, 6]
• Fatigue [1, 6]
• Weight loss with no apparent reason [4, 6]
• Painful or frequent urination [6, 9]
• Dark urine [4]
• Frequent urination and urgency [4]
• Urinary hesitancy [4]

It's essential to note that these symptoms can also be indicative of other health conditions. If you experience any of these symptoms, it is crucial to consult a doctor for proper evaluation and diagnosis.

In the early stages, renal pelvis carcinoma may not cause any noticeable signs or symptoms. However, as the tumor grows or spreads, more pronounced symptoms may develop [14].

Diagnostic Tests for Renal Pelvis Carcinoma

Renal pelvis carcinoma, also known as ureteral cancer, can be diagnosed using various diagnostic tests. These tests help identify the presence and extent of the cancer.

• Urinalysis: A test to check the color and contents of urine may show blood in the urine, which is a common symptom of renal pelvis carcinoma [4].
• Complete Blood Count (CBC): A CBC may show anemia, which can be a sign of renal pelvis carcinoma [4].
• Urine Cytology: This test involves microscopic examination of urine to detect abnormal cells that could indicate cancer [3].
• CT Urography: A CT scan with contrast dye is used to visualize the urinary tract and identify any abnormalities, such as tumors or blockages [7].
• Cystoscopy: This procedure allows doctors to visually examine the inside of the bladder and ureters using a flexible tube with a camera and light on the end [7].
• Biopsy: A biopsy may be performed to confirm the diagnosis by examining tissue samples from the affected area.

These diagnostic tests help healthcare providers determine the stage and extent of renal pelvis carcinoma, which is essential for developing an effective treatment plan.

Chemotherapy Regimens for Renal Pelvis Carcinoma

The treatment of transitional cell cancer of the renal pelvis and ureter often involves surgery, but in cases of metastatic or recurrent disease, chemotherapy regimens are commonly used. According to search result [1], chemotherapy regimens for metastatic bladder cancer are often employed in treating this type of cancer.

Regional Treatment with Chemotherapy

Regional treatment, which involves placing chemotherapy directly into the renal pelvis or ureter, is another method used to treat transitional cell cancer of the renal pelvis and ureter. This approach mainly affects cancer cells in those areas [2].

Commonly Used Chemotherapy Agents

The most commonly used chemotherapy agents for treating this type of cancer are mitomycin and gemcitabine [5]. Patients may also receive systemic chemotherapy depending on the severity and recurrence of the disease.

Immunotherapy and Targeted Therapy

In addition to chemotherapy, treatment for advanced kidney cancer may involve a combination of immunotherapy and targeted therapy medications. These can help shrink a tumor, slow its growth, or reduce the risk of cancer returning [13].

FDA-Approved Medications

The US Food and Drug Administration has approved mitomycin pyelocalyceal (Jelmyto) for treatment of low-grade upper tract urothelial cancer [4]. Jelmyto is a medication used to treat this type of cancer, which occurs in the upper urinary tract.

References:

[1] Transitional cell cancer of the renal pelvis and ureter treatment is primarily surgery. In metastatic or recurrent disease, chemotherapy regimens for metastatic bladder cancer are often used. [2] Regional treatment for transitional cell cancer of renal pelvis and ureter is a method of placing the chemotherapy or immunotherapy drug directly into the renal pelvis or the ureter to mainly affect cancer cells in those areas. [4] Apr 7, 2023 — In 2020 the US Food and Drug Administration approved mitomycin pyelocalyceal (Jelmyto) for treatment of low-grade upper tract urothelial cancer ... [5] Apr 7, 2023 — Most commonly used chemotherapy agents are mitomycin and gemcitabine. [24] Patients may also receive systemic chemotherapy depending on severity and recurrence ... [13] Treatment for advanced kidney cancer may involve a combination of immunotherapy and targeted therapy medications. These can shrink a tumor, slow its growth, or reduce the risk of cancer returning.

The differential diagnosis for renal pelvis carcinoma involves considering various conditions that can present similarly to this type of cancer.

• Clear cell renal cell carcinoma: This is a common type of kidney cancer that can invade the renal pelvis, making it a key differential diagnosis (1).
• Transitional cell cancer of the renal pelvis and ureter: This is a rare type of urinary tract cancer that typically affects adults ages 65 and older (3), and can be considered in the differential diagnosis for renal pelvis carcinoma.
• Spindle cell sarcomas: These are a variety of rare tumors that can involve the renal pelvis, and should be considered in the differential diagnosis (4).
• Xanthogranulomatous pyelonephritis (XGP): This is a rare condition characterized by inflammation of the kidney and renal pelvis, which can lead to hydronephrosis and form masses that may mimic tumors (7).

It's worth noting that the differential diagnosis for renal pelvis carcinoma can be complex and requires careful consideration of various factors, including radiographic appearance and histologic features.

References: * [1] The main differential diagnosis is with secondary invasion by a clear cell renal cell carcinoma. Some cases can be problematic (8). * [3] Transitional cell cancer of the renal pelvis and ureter is a rare urinary tract cancer that typically affects adults ages 65 and older (10). * [4] The differential diagnosis for these lesions includes a variety of spindle cell sarcomas and secondary infiltration of the renal pelvis by sarcomatoid renal ... (5) * [7] The main differential diagnosis of renal SCC is XGP, a structure also associated with renal calculi that leads to hydronephrosis and forms masses (7)